Minoryx Therapeutics Entered into a License Agreement with Neuraxpharm for Leriglitazone to Treat Rare Central Nervous System Disease
Shots:
- Minoryx to receive up front & is eligible to receive milestones and development funding of ~$256M along with royalties
- Neuraxpharm gets an exclusive right to commercialize leriglitazone (selective PPAR gamma agonist) in the EU and continues to collaborate with Minoryx to advance the development of leriglitazone while Minoryx holds the full rights to leriglitazone in the US and globally (ex- China)
- If Leriglitazone is approved in the EU, it will be the first approved treatment for adult male patients with X-ALD. Both companies continue to advance the therapy for additional X-ALD patient populations and other orphan indications
Ref: Neuraxpharm | Image: Neuraxpharm
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
